Besifloxacin in the management of bacterial infections of the ocular surface.

[1]  J. Parekh,et al.  Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial keratitis: a retrospective safety surveillance study. , 2015, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[2]  T. Morris,et al.  In vitro Antibiotic Susceptibility Profile of Ocular Pathogens - Results from the First ARMOR Canada Surveillance Study , 2014 .

[3]  T. Morris,et al.  Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens , 2014 .

[4]  T. Morris,et al.  The Safety of Besifloxacin Ophthalmic Suspension 0.6 % Used Three Times Daily for 7 Days in the Treatment of Bacterial Conjunctivitis , 2013, Drugs in R&D.

[5]  Jonathan S. Chang,et al.  Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci. , 2013, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[6]  Darlene Miller,et al.  Pharmacological treatment for infectious corneal ulcers , 2013, Expert opinion on pharmacotherapy.

[7]  J. Jamart,et al.  Fluoroquinolones or fortified antibiotics for treating bacterial keratitis: systematic review and meta-analysis of comparative studies. , 2012, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[8]  T. Morris,et al.  Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections , 2012, Clinical ophthalmology.

[9]  A. Sheikh,et al.  Antibiotics versus placebo for acute bacterial conjunctivitis. , 2012, The Cochrane database of systematic reviews.

[10]  Raymond L. M. Wong,et al.  New Treatments for Bacterial Keratitis , 2012, Journal of ophthalmology.

[11]  J. Y. Ku,et al.  Shifting trends in bacterial keratitis in Toronto: an 11-year review. , 2012, Ophthalmology.

[12]  Kirk M. Bateman,et al.  Besifloxacin Ophthalmic Suspension 0.6% Administered Twice Daily for 3 Days in the Treatment of Bacterial Conjunctivitis in Adults and Children , 2012, Clinical Drug Investigation.

[13]  T. O'brien.  Besifloxacin Ophthalmic Suspension, 0.6%: a Novel Topical Fluoroquinolone for Bacterial Conjunctivitis , 2012, Advances in Therapy.

[14]  T. Morris,et al.  Microbiological Etiology and Susceptibility of Bacterial Conjunctivitis Isolates from Clinical Trials with Ophthalmic, Twice-Daily Besifloxacin , 2012, Advances in Therapy.

[15]  B. Carreras.  Análisis bacteriológicos en el tratamiento de las conjuntivitis: Comparación de la resistencia a antibióticos entre 1982 y 2008 , 2012 .

[16]  B. Carreras.  Bacteriological analysis in the management of conjunctivitis. Comparison of antibiotic resistance between 1982 and 2008 , 2012 .

[17]  A. Gurbaxani,et al.  Antibiotic resistance in microbial keratitis: ten-year experience of corneal scrapes in the United Kingdom. , 2011, Ophthalmology (Rochester, Minn.).

[18]  T. Morris,et al.  Topoisomerase Mutations That Are Associated with High-Level Resistance to Earlier Fluoroquinolones in Staphylococcus aureus Have Less Effect on the Antibacterial Activity of Besifloxacin , 2011, Chemotherapy.

[19]  T. Morris,et al.  Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study. , 2011, American journal of ophthalmology.

[20]  R. Provine,et al.  When the Whites of the Eyes are Red: A Uniquely Human Cue , 2011 .

[21]  T. Morris,et al.  In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride. , 2011, The Journal of antimicrobial chemotherapy.

[22]  T. Morris,et al.  Evaluation of the Effect of Bacterial Efflux Pumps on the Antibacterial Activity of the Novel Fluoroquinolone Besifloxacin , 2011, Journal of chemotherapy.

[23]  R. Gold.  Treatment of bacterial conjunctivitis in children. , 2011, Pediatric annals.

[24]  A. Shafiee,et al.  Comparison of Besifloxacin, Gatifloxacin, and Moxifloxacin Against Strains of Pseudomonas aeruginosa With Different Quinolone Susceptibility Patterns in a Rabbit Model of Keratitis , 2011, Cornea.

[25]  T. Morris,et al.  Molecular Epidemiology of Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Isolated from the Eye , 2010, Current eye research.

[26]  T. Comstock,et al.  Limitations of Current Antibiotics for the Treatment of Bacterial Conjunctivitis , 2010, Optometry and vision science : official publication of the American Academy of Optometry.

[27]  J. Blondeau,et al.  Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones. , 2010, Journal of cataract and refractive surgery.

[28]  T. Morris,et al.  Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae , 2010, The Journal of antimicrobial chemotherapy.

[29]  A. Shafiee,et al.  Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis. , 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[30]  T. Comstock,et al.  Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration , 2010, Clinical ophthalmology.

[31]  M. Pichichero,et al.  Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% in Children and Adolescents with Bacterial Conjunctivitis , 2010, Paediatric drugs.

[32]  Andrew F. Smith,et al.  Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States , 2009, BMC ophthalmology.

[33]  C. Hutnik,et al.  Evidence-based treatment of acute infective conjunctivitis: Breaking the cycle of antibiotic prescribing. , 2009, Canadian family physician Medecin de famille canadien.

[34]  A. Shafiee,et al.  Efficacy of Besifloxacin in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Keratitis , 2009, Cornea.

[35]  T. Morris,et al.  Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. , 2009, Ophthalmology.

[36]  K. Ward,et al.  Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. , 2009, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[37]  J. Blondeau,et al.  Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains. , 2009, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[38]  T. Morris,et al.  Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic Bacteria , 2009, Antimicrobial Agents and Chemotherapy.

[39]  T. Morris,et al.  Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis , 2009, Current medical research and opinion.

[40]  Alexandra Aubry,et al.  Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. , 2009, The Journal of antimicrobial chemotherapy.

[41]  T. Comstock,et al.  Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. , 2009, Clinical therapeutics.

[42]  B. Jeng,et al.  Bacterial conjunctivitis: a review for internists. , 2008, Cleveland Clinic journal of medicine.

[43]  M. Raizman,et al.  Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. , 2008, American journal of ophthalmology.

[44]  G. Høvding.  Acute bacterial conjunctivitis , 2008, Acta ophthalmologica.

[45]  H. Taylor,et al.  Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. , 2007, Ophthalmology.

[46]  P. Rose.  Management strategies for acute infective conjunctivitis in primary care: a systematic review , 2007, Expert opinion on pharmacotherapy.

[47]  K. Ward,et al.  Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. , 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[48]  W. Feuer,et al.  Update on bacterial conjunctivitis in South Florida. , 2006, Ophthalmology.

[49]  A. Sheikh,et al.  Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial , 2005, The Lancet.

[50]  Gerben ter Riet,et al.  Predicting bacterial cause in infectious conjunctivitis: cohort study on informativeness of combinations of signs and symptoms , 2004, BMJ : British Medical Journal.

[51]  D. Hwang.  Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. , 2004, Survey of ophthalmology.

[52]  G. Alexandrakis,et al.  Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. , 2000, Ophthalmology.

[53]  J. Baum,et al.  Emerging fluoroquinolone resistance in bacterial keratitis: A 5-year review , 1999 .

[54]  P. McDonnell.  How do general practitioners manage eye disease in the community? , 1988, The British journal of ophthalmology.

[55]  L. Scott,et al.  Besifloxacin Ophthalmic Suspension 0.6% , 2012, Drugs.

[56]  Kirk M. Bateman,et al.  Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. , 2011, Clinical therapeutics.

[57]  S. Mccormick,et al.  Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear Infirmary , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[58]  T. Comstock,et al.  Safety and Tolerability of Besifloxacin Ophthalmic Suspension 0.6% in the Treatment of Bacterial Conjunctivitis , 2010, Clinical drug investigation.

[59]  R. Kowalski,et al.  Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. , 1999, Ophthalmology.

[60]  T. Morris,et al.  Clinical Ophthalmology Dovepress , 2022 .